Pacific Biosciences Of California (PACB) EBIT Margin (2010 - 2026)

Pacific Biosciences Of California's EBIT Margin history runs 17 years deep, the most recent figure standing at 22.48% for Q1 2026.

• On a quarterly basis, EBIT Margin rose 113203.0% year-over-year to 22.48% in Q1 2026; TTM through Mar 2026 was 83.29%, a 45616.0% increase from a year earlier, with the FY2025 full-year figure at 346.15%, down 3818.0% from the prior year.
• EBIT Margin grew to 22.48% in Q1 2026 per PACB's latest filing, from 92.28% in the prior quarter.
• Across five years, EBIT Margin topped out at 22.48% in Q1 2026 and bottomed at 1154.51% in Q1 2025.
• The 5-year median for EBIT Margin is 191.64% (2022), against an average of 258.4%.
• Across the five-year window, EBIT Margin plunged 94487 bps in 2025 and surged 113203 bps in 2026, its largest moves.
• Year by year, EBIT Margin stood at 318.37% in 2022, then surged by 53 bps to 150.02% in 2023, then tumbled by 160 bps to 390.14% in 2024, then soared by 76 bps to 92.28% in 2025, then jumped by 76 bps to 22.48% in 2026.
• Per Business Quant, the three latest PACB EBIT Margin figures stand at 22.48% (Q1 2026), 92.28% (Q4 2025), and 101.13% (Q3 2025).